US Pharma MarketingThe post ERS 2026: Sanofi’s lunsekimig hits Phase IIb goals in asthma, Phase III set to follow appeared first on Clinical Trials Arena.
ERS 2026: Sanofi's lunsekimig hits Phase IIb goals in asthma, Phase III set to follow
The data expands on a readout earlier this year when Sanofi revealed the trial had its primary endpoint. The data expands on a readout earlier this year when Sanofi revealed the trial had its primary endpoint. The trial enrolled 685 adults with moderate to severe asthma on standard of care (SoC) treatment excluding smokers. Credit: brizmaker/Shutterstock.com. Unlock FREE Access to Premium Content Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation. With a free Clinical Trials Arena profile, you can: Experience unmatched clarity with a single platform that combines unique…
The data expands on a readout earlier this year when Sanofi revealed the trial had its primary endpoint.
Source: Clinical Trials Arena